Tumor-driven evolution of immunosuppressive networks during malignant progression.
about
Cancer immunoediting from immune surveillance to immune escapeMolecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling UnitsUnderground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsCancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers.Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defensesA new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandinsHarnessing the power of Vδ2 cells in cancer immunotherapyUnderstanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Cancer: evolutionary, genetic and epigenetic aspectsThe spectrum of resistance in SR/CR mice: the critical role of chemoattraction in the cancer/leukocyte interactionCancer immunotherapy: how low-level ionizing radiation can play a key role.Investigation of HIFU-induced anti-tumor immunity in a murine tumor modelExpression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas.Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion.CA125 in ovarian cancerExploiting the critical perioperative period to improve long-term cancer outcomesCirculating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas.Ipilimumab augments antitumor activity of bispecific antibody-armed T cellsPerspectives for preventive and therapeutic HPV vaccines.Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).Immunotherapy for cervical cancer: Research status and clinical potentialTumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive.Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins.Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer.Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.Releasing the brake on the immune system: ipilimumab in melanoma and other tumorsDifferential impact of IL-10 expression on survival and relapse between HPV16-positive and -negative oral squamous cell carcinomas.Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.A cytokine-mediated link between innate immunity, inflammation, and cancer.Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.Pulmonary mycobacterial granuloma increased IL-10 production contributes to establishing a symbiotic host-microbe microenvironment.Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas.Myelopoietic efficacy of orlistat in murine hosts bearing T cell lymphoma: implication in macrophage differentiation and activationThe role of complement in tumor growthDecrease in CD8+ lymphocyte number and altered cytokine profile in human prostate cancerTumour macrophages as potential targets of bisphosphonates.T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology.Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis.Immunosuppressive tumor microenvironment in cervical cancer patients
P2860
Q24655415-8F664826-C2EF-4C06-A896-5DF810251BEEQ26744973-9364EC53-D798-43E6-99F6-9AEBEE129B6BQ26751011-11C79055-3926-47E1-832F-76601CAC322EQ26830028-D8BEE792-832E-4844-B0E7-FEE79963926CQ27001081-2C6023E5-8CC4-41AB-AA67-DE38107F6B75Q27021528-D23D2FA4-C258-442D-9445-B1A631ED77F8Q27027547-2F2E5FC4-2188-4F81-A6BC-6CD19CF2E17CQ27691330-D3CE4C30-AD3A-4C56-BD2B-8DF568C8DB14Q28728960-46677879-BF77-40D8-BFA7-C0EAA5CA197DQ28972215-29D1FA17-F69A-4164-ABC8-F65ED2F87D5CQ30235014-B6FFE987-B07E-4894-A402-2A4EBC210215Q30502120-DB2B92F9-9379-41AF-AA62-FEFCD5FAB95DQ33325701-1361F59D-7F1C-4887-B871-8AB6EBF35EFBQ33730111-DAB5C70A-765F-4E61-9559-5CFD7ED7DEACQ33859857-620699F9-015B-4F78-AEFC-077ADD65DA29Q33871661-9497E094-463B-42A0-9D9E-422A45FC788EQ33890619-6F3836CF-925D-4E03-BD26-BD246D9CFCB4Q33929184-7F3AAC34-070F-42E4-9818-83975A11C9D2Q34011494-91269173-41F8-418C-824F-12A08C04882AQ34028872-F7E0BB58-A3FC-474F-8D45-51C2B9E0F30CQ34033763-A07E3E46-512F-48F5-A374-056FC6F50625Q34113544-C902C3F9-5709-4059-A925-54EA8303EBC4Q34181909-5DAFC523-1FF4-4726-8FCC-71E3780FCD21Q34276522-2FFD12C9-C369-4489-B00E-3B1455BC143FQ34357788-17FFD4D3-547D-4BF9-8EAE-FE7277D07BAAQ34412294-6D848237-646E-43D4-B135-F4ED02AA4E2FQ34447732-D3EACD58-2089-4BF4-8ECE-068158EFB217Q34464484-E536D58B-0EAE-4941-B9A4-8CC5A6B6E12DQ34537725-1183F56F-86F9-4BCC-802E-56F6751ABB81Q34625152-4E98431B-3DF8-42F1-8B03-F6952E1E6B82Q34655953-AFE971F5-DBD4-4459-8C2A-714C11C41798Q34805778-167255D5-AB6F-42FB-B5AC-0B3915E45006Q34914935-26A2870E-CB5A-40B4-8B3D-8DCA4F2AC376Q35070248-EF365599-2795-41D1-8DC0-F275EFB672B7Q35231345-F6CACBB6-338D-4EBB-BFB0-BBDE7F29E9C4Q35232395-B43F4AA8-5BAE-4B51-B9A0-EB4514176F6AQ35547309-4CBEFCD1-4394-41FA-B7A8-D867A4F3A16AQ35550879-6E83637B-1C37-4A08-A71F-8B07EC4BCB97Q35551409-A0174858-E488-497E-97CD-CE5257CB1915Q35603131-6AB59854-0191-44ED-B58D-9F296542C5D1
P2860
Tumor-driven evolution of immunosuppressive networks during malignant progression.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Tumor-driven evolution of immunosuppressive networks during malignant progression.
@ast
Tumor-driven evolution of immunosuppressive networks during malignant progression.
@en
type
label
Tumor-driven evolution of immunosuppressive networks during malignant progression.
@ast
Tumor-driven evolution of immunosuppressive networks during malignant progression.
@en
prefLabel
Tumor-driven evolution of immunosuppressive networks during malignant progression.
@ast
Tumor-driven evolution of immunosuppressive networks during malignant progression.
@en
P2093
P1433
P1476
Tumor-driven evolution of immunosuppressive networks during malignant progression.
@en
P2093
Kazuaki Tanabe
Koji Arihiro
Manabu Emi
Ryungsa Kim
P304
P356
10.1158/0008-5472.CAN-05-4128
P407
P577
2006-06-01T00:00:00Z